Want to see DE:AJ91 full AI Analyst Report?
AJ91 Stock Chart & Stats
€12.60
€0.00(0.00%)
At close: 4:00 PM EST
€12.60
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€10.80 - €15.90
Previous CloseN/A
Volume200.00
Average Volume (3M)1.04K
Market Cap
€58.35M
Enterprise Value€50.57M
Total Cash (Recent Filing)€18.54M
Total Debt (Recent Filing)€4.16M
Price to Earnings (P/E)11.0
Beta0.58
Next Earnings
Aug 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield6.36%
Share Statistics
EPS (TTM)1.05
Shares Outstanding5,073,816
10 Day Avg. Volume577
30 Day Avg. Volume1,041
Financial Highlights & Ratios
PEG Ratio12.18
Price to Book (P/B)1.50
Price to Sales (P/S)1.13
P/FCF Ratio23.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetDocCheck’s very low leverage (debt ≈ 0.10x equity in 2025) and sizeable equity relative to assets provide durable financial flexibility. This conservatism reduces refinancing and solvency risk, supports investment or dividend capacity, and cushions the business during cyclical revenue swings.
Specialized, Verified Healthcare Professional NetworkThe company’s core asset— a verified professional healthcare community and specialized B2B offerings—creates a durable competitive position. Focused industry relevance and trusted access to HCPs support recurring revenue from marketing, content and platform services, making client relationships stickier over time.
Healthy Margins And Profitability ResilienceDespite revenue volatility, DocCheck sustains high‑teens EBITDA and about 10% net margins, demonstrating structural cost discipline and pricing power. Persistent margins support cash generation, dividend capacity and reinvestment potential even if topline growth moderates in the medium term.
Bears Say
Volatile Revenue And 2025 DeclineThe sustained revenue volatility and the explicit decline in 2025 weaken predictability of top‑line performance. For a B2B services provider, uneven sales hinder capacity planning and limit the ability to steadily scale margins or fund multi‑year growth initiatives without relying on one‑off measures.
Weaker Free Cash Flow And Cash ConversionA sharp drop in free cash flow and operating cash covering only ~50%+ of accounting profit indicate weakening cash quality. This reduces available internal funds for capex, acquisitions or dividends and increases sensitivity to working‑capital swings, constraining strategic flexibility.
Uneven Operating Performance And Normalized GrowthOperating results have normalized below the 2020–2021 peaks and remain inconsistent. This suggests a lower structural growth trajectory and intermittent operating leverage benefits, making sustained expansion and improvements in return metrics less certain over the next several quarters.
DocCheck AG News
AJ91 FAQ
What was DocCheck AG’s price range in the past 12 months?
DocCheck AG lowest stock price was €10.80 and its highest was €15.90 in the past 12 months.
What is DocCheck AG’s market cap?
DocCheck AG’s market cap is €58.35M.
When is DocCheck AG’s upcoming earnings report date?
DocCheck AG’s upcoming earnings report date is Aug 04, 2026 which is in 33 days.
How were DocCheck AG’s earnings last quarter?
DocCheck AG released its earnings results on Feb 06, 2026. The company reported €0.567 earnings per share for the quarter, beating the consensus estimate of N/A by €0.567.
Is DocCheck AG overvalued?
According to Wall Street analysts DocCheck AG’s price is currently Overvalued.
Does DocCheck AG pay dividends?
DocCheck AG pays a Annually dividend of €1 which represents an annual dividend yield of 6.36%. See more information on DocCheck AG dividends here
What is DocCheck AG’s EPS estimate?
DocCheck AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does DocCheck AG have?
DocCheck AG has 5,073,816 shares outstanding.
What happened to DocCheck AG’s price movement after its last earnings report?
DocCheck AG reported an EPS of €0.567 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of DocCheck AG?
Currently, no hedge funds are holding shares in DE:AJ91
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
DocCheck AG Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
58.71%
12-Months-Change
Fundamentals
Return on Equity
13.28%
Trailing 12-Months
Asset Growth
-8.52%
Trailing 12-Months
Company Description
DocCheck AG
DocCheck AG offers community, agency, and e-commerce services for the healthcare sector in Europe. The company develops and implements communication strategies for media on healthcare and business-to-business sectors; sells medical supplies and medical technology primarily via mail order to various medical professional groups, and invests in healthcare sectors, as well as involved in online advertising, market research, online studies, and paid content for healthcare market players. It also operates platform for information exchange, online services, and e-commerce in this market. DocCheck AG was founded in 1990 and is based in Cologne, Germany.
Technical Analysis
CompuGroup Medical
―
MeVis Medical Solutions
―
Medios AG
―
MediNavi AG
―
Novetum AG
―